<DOC>
	<DOCNO>NCT01338337</DOCNO>
	<brief_summary>Primary Outcome Measures : • To evaluate efficacy treatment Azacitidine patient transfusion-dependent , low risk International Prognostic Scoring System ( IPSS ) 0 int-1 , Myelodysplastic Syndrome ( MDS ) without chromosome 5 ( 5q ) deletion . The main objective base erythroid haematologic response accord International Working Group ( IWG ) 2006 criterion . Secondary Outcome Measures : - Haematologic response , base follow parameter : platelet , neutrophil accord International Working Group ( IWG ) Criteria . - Medullary cytogenetic response accord International Working Group ( IWG ) 2006 criterion . - The effect treatment response quality life , Functional Assessment Cancer Therapy-Anemia ( FACT-an ) questionnaire . - Overall survival , Event-Free Survival Acute Leukaemia Transformation Rate .</brief_summary>
	<brief_title>Study Vidaza ( Azacitidine ) Versus Support Treatment Patients With Low Risk Myelodysplastic Syndrome ( Low Intermediate-1 IPSS ) Without 5q Deletion Transfusion Dependent Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>1 . Patients 18 year age . 2 . Patients agree take part study must understand informed consent sign voluntarily . 3 . Patients must able comply program visit study requirement . 4 . Patients low risk International Prognostic Scoring System ( IPSS 0 Int1 ) myelodysplastic syndrome ( MDS ) without chromosome 5 ( 5q ) deletion anaemia transfusion need . Transfusion dependence define least 2 unit erythrocyte concentrate ( EC ) 8 week prior inclusion study , symptomatic anaemia , define haemoglobin value ≤9.0 gr/dl . 5 . Patients respond previous treatment erythropoietin ( EPO ) : With response profile base basal erythropoietin ( EPO ) level &gt; 250 u/L , response alter 12 week treatment maximum dos ( 60.000 U 250 µg darbepoetin ( DAB ) , combination Granulocyte colonystimulating factor ( GCSF ) case refractory anaemia ring sideroblast ( RARS ) ) , loss response obtain initial optimum response . 6 . Patients candidate intensive chemotherapy transplant modality . 7 . Patients Eastern Cooperative Oncology Group ( ECOG ) score ≤ 3 8 . Women childbearing age heterosexual men whose partner childbearing age , must undertake use effective contraceptive method duration treatment least 3 month alter finalise . 1 . The presence psychiatric medical disease prevents patient signing informed consent . 2 . Human immunodeficiency virus ( HIV ) Seropositive , hepatitis B antigen ( AgVHB ) positive hepatitis C virus ( HCV ) polymerase chain reaction ( PCR ) positive . 3 . Pregnant nursing woman . 4 . Uncontrolled intercurrent disease : Active infection require parenteral antibiotic , Symptomatic chronic heart failure ( New York Heart Association ( NYHA ) class III IV ) , Instable angina pectoris , Another neoplasia apart myelodysplastic syndrome ( MDS ) . 5 . Have treat demethylating drug moment prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Low risk International Prognostic Scoring System ( IPSS ) ( 0 Int-1 )</keyword>
	<keyword>Patients respond previous treatment erythropoietin ( EPO )</keyword>
	<keyword>Eastern Cooperative Oncology Group ( ECOG ) score ≤ 3</keyword>
</DOC>